GlobalData has released its new
Country report, PharmaPoint: Meningococcal Vaccines Brazil Drug Forecast and
Market Analysis to 2022. Meningococcal disease is an acute infection caused by
the gram-negative bacterium Neisseria meningitidis. Its rapid onset and
severity of symptoms makes prompt and effective diagnosis and treatment nearly
impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra
and Novartis Menveo, account for the vast majority of global sales, with the US
adolescent market being the key target segment. GlobalData expects growth in
the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment
landscape. Vaccines that better protect infants and/or provide a longer
duration of immunity also have an opportunity to seize market share during
2012-2022.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-brazil-drug-forecast-and-market-analysis-to-2022
GlobalData predicts that market
share for private vaccine manufacturers to virtually disappear over the course
of the forecast, with Brazil unleashing domestically-produced MenC conjugate
vaccines that are more cost-effective for the government-funded healthcare
system. These vaccines, which include a MenC conjugate vaccine and a
heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and
produced by government-sponsored institutions such as Bio-Manguinhos, Instituto
Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines
will quickly steal market share from private manufacturers because of their
cost-effectiveness advantage.
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Brazil from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Brazil Meningococcal Vaccines market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Brazil
About Us
MarketResearchReports.Biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment